Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Pulmonology
  • Pulmonology Perspective
  • Role of...

Role of Cefepime/Enmetazobactam in Ventilator-associated Pneumonia (VAP)

Dr. Kamal Kant KohliWritten by Dr. Kamal Kant Kohli Published On 2024-11-04T11:00:39+05:30  |  Updated On 4 Nov 2024 4:45 PM IST
Role of Cefepime/Enmetazobactam in Ventilator-associated Pneumonia (VAP)
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Key Takeaways:

  • Ventilator-associated pneumonia (VAP) is the most common ICU infection, affecting up to 20% of critically ill patients with a mortality rate of approximately 13%, significantly increasing the healthcare burden.
  • Gram-negative bacilli, especially multidrug-resistant pathogens like Pseudomonas spp., Acinetobacter spp., and ESBL-producing Enterobacteriaceae, as well as Staphylococcus aureus, are the main causative agents of VAP.
  • Cefepime-Enmetazobactam, a novel β-lactam–β-lactamase inhibitor combination, shows strong activity against ESBL and Amp C-producing Gram-negative pathogens, with effective lung penetration and a favorable safety profile.
  • The Central Drugs Standard Control Organization(CDSCO, India) (1), the European Medicines Agency (EMA), and the United Kingdom Medicines and Healthcare Products Regulatory Agency (UKMHRA) (2) approved the combination of cefepime/enmetazobactam in 2024 for the treatment ventilator-associated pneumonia (VAP) in patients who are 18 years of age or older.

Ventilator-associated pneumonia (VAP) is the most prevalent healthcare-associated infection in intensive care units, impacting up to 20% of critically ill patients worldwide. This condition not only increases the use of antibiotics but also contributes significantly to antibiotic resistance, posing a serious public health challenge.(3)

Ventilator-associated Pneumonia (VAP) -Healthcare Burden in India: In India, VAP carries a mortality rate of approximately 13%. The majority of infections (about 58%) are attributed to Gram-negative bacilli, with Staphylococcus aureus responsible for approximately 20% of cases. Notably, common multidrug-resistant (MDR) pathogens include Pseudomonas spp., Acinetobacter spp., and Enterobacteriaceae that produce extended-spectrum β-lactamases (ESBL), AmpC, or metallo-β-lactamases (MBL). (4)

VAP is associated with significantly longer hospital stays, averaging about 21 days compared to just 8.2 days for non-VAP patients. This extended hospitalization places considerable strain on healthcare resources, with treatment costs reaching approximately INR 544,467 for VAP patients, contrasted with INR 207,416 for those without the infection. (5)Given these challenges, effective prevention and management strategies for VAP are essential for improving patient outcomes and reducing healthcare costs. In this context, exploring the role of cefepime/enmetazobactam as a treatment option for VAP is particularly relevant.

Cefepime-Enmetazobactam for Ventilator-Associated Pneumonia:

A demographic study among 20 participants assesses the pharmacokinetics, safety, and clinical efficacy of cefepime-enmetazobactam, a β-lactam–β-lactamase inhibitor combination, for the treatment of nosocomial pneumonia, especially VAP. This combination exhibits strong activity against Enterobacteriaceae, including ESBLs and AmpC, providing a promising carbapenem-sparing alternative. Key findings include:

  • Pharmacokinetics: Cefepime-enmetazobactam showed similar behavior in plasma and epithelial lining fluid(ELF), with mean drug partitioning of 60.59% for cefepime and 53.03% for enmetazobactam, indicating effective lung penetration.
  • Monte Carlo Simulations: Cefepime-enmetazobactam demonstrates near 100% joint probability of target attainment (PTA) in ELF for ESBL-producing Klebsiella pneumoniae isolates with a MIC of ≤4 mg/L, and 94.4% and 78.1% for MICs of 8 mg/L and 16 mg/L, respectively. This efficacy supports its potential as a reliable treatment option, particularly in overcoming resistant infections. (Figure 1)
  • Safety Profile: Well tolerated with no serious adverse events leading to discontinuation.(6)

Figure 1: The probability of target attainment in epithelial lining fluid (ELF), shown as solid circles, is plotted alongside the distribution of minimum inhibitory concentration (MIC) values for cefepime-enmetazobactam against 102 ESBL-producing Klebsiella pneumoniae isolates, represented by solid squares.

Given its broad-spectrum efficacy, safety, and favorable pharmacokinetic properties, cefepime-enmetazobactam presents a strong candidate for use in treating VAP, potentially allowing for carbapenem-sparing strategies.(6)

Cefepime/enmetazobactam offers a promising option for managing VAP, effectively targeting ESBL and AmpC-producing Gram-negative pathogens and reducing reliance on carbapenems.

References:

1. DCGI Approval for antibiotic drug combination of cefepime and enmetazobactam. Retrieved oon 15th July 2024 from https://www.expresspharma.in/orchid-pharma-receives-dcgi-approval-for-its-antibiotic-drug-combination-of-cefepime-and-enmetazobactam-nce/

2. Keam SJ. Cefepime/Enmetazobactam: First Approval. Drugs. 2024 Jun;84(6):737-744. doi: 10.1007/s40265-024-02035-2. Epub 2024 May 18. PMID: 38761353.

3. Howroyd, F., Chacko, C., MacDuff, A. et al. Ventilator-associated pneumonia: pathobiological heterogeneity and diagnostic challenges. Nat Commun 15, 6447 (2024). https://doi.org/10.1038/s41467-024-50805-z

4. Thakur HK, Tarai B, Bhargava A, et al. Pathogenesis, Diagnosis and Therapeutic Strategies for Ventilator-associated Pneumonia. J Pure Appl Microbiol. 2024;18(2):772-796. doi: 10.22207/JPAM.18.2.10

5. Thimmaiah, Guruprasad1; Pandey, Navin1; Prinja, Shankar2; Jain, Kajal3; Biswal, Manisha4; Agarwal, Ritesh5; Koushal, Vipin1; Sethi, Saru1. Ventilator-associated pneumonia – What price does the public health system pay?. Lung India 41(4):p 278-283, Jul–Aug 2024. | DOI: 10.4103/lungindia.lungindia_597_23

cefepimeenmetazobactamcefepime enmetazobactamvapventilator assisted pneumoniacefepime in vapenmetazobactam in vapcefepime enmetazobactam in vapesblocipcipenmetcipenment in vapesblocip in vap
Dr. Kamal Kant Kohli
Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

Show Full Article
Next Story

Editorial

Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

Relevance of Pioglitazone in Indian T2DM Care Continuum

Relevance of Pioglitazone in Indian T2DM Care Continuum

Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

View All

Journal Club Today

Study Reveals Why Your Immune System Works Better in Daylight

Study Reveals Why Your Immune System Works Better in Daylight

View All

Health News Today

Health Bulletin 30/May/2025

Health Bulletin 30/May/2025

View All
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok